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Previewsmay be developed to effectively treat
neurological diseases, particularly those
caused by cellular dysfunction or tissue
injury.
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Itch is immensely frustrating. Most studies focus on the cause of itch. In this issue of Neuron, Kardon et al.
(2014) find that itch can be modulated by inhibitory neurons that produce dynorphin, an endogenous agonist
of k-opioid receptors.Scientific investigations can be likened to
scratch tickets. While individual experi-
ments that we perform may not pan out,
the study by Kardon et al. (2014) in this
issue of Neuron is a winner. These inves-
tigators characterize a population of
spinal inhibitory neurons and demon-
strate that dynorphin, released from these
neurons, is a backscratcher responsible
for modulating itch (Figure 1).
Itch, also referred to as pruritus, may
have evolved as a protective mechanism
against threats from arthropods, but it is
a prominent feature of inflammatory skin
disease and ruins the lives of patients
with chronic renal failure, liver disease,
and certain malignancies. Its impact on
quality of life is comparable to that ofpain (Kini et al., 2011). It has been sug-
gested that itch be considered a disease
(Yosipovitch, 2011). Drugs with itch as
an approved indication are limited to
antihistamines and topical steroids and
have limited effectiveness. It is recog-
nized that neuromodulators can be re-
markably effective in treating some itches
and that scratching may provide tem-
porary relief and feel pleasurable, sug-
gesting that complex neurocircuitry
and neuromodulatory mechanisms are
involved. Accordingly, endogenous mole-
culesmay have the potential to reduce the
sensation of itch.
Understanding the underlying mecha-
nisms of itch is an intense focus of inves-
tigation. Recent advances include theidentification of a series of itch-related
ligands and receptors as well as peri-
pheral neurons and spinal afferents
specialized in transmitting this sensation
and distinguishing it from pain (Han
et al., 2013; Mishra and Hoon, 2013). It
is recognized that itch and pain are part
of a complex family dynamic. A few exam-
ples are scratching, which alleviates itch
but is a noxious stimulus, m-opioids,
which relieve pain but induce itch, and
the inhibition of glutaminergic transmis-
sion from nociceptors, which reduces
pain but increases scratching (Lager-
stro¨m et al., 2010; Liu et al., 2010).
A key role in sensory processes has
been suggested for inhibitory circuits in
the spinal cord, consistent with then 82, May 7, 2014 ª2014 Elsevier Inc. 503
Figure 1. Interneurons that Release Dynorphin Modulate Itch
Neurons that respond to itch, cold, and noxious stimuli innervate and are modulated by B5-I interneurons
that produce dynorphin. Capsaicin, mustard oil, and menthol activate TRPV1, TRPA1, and TRPM8,
respectively. B5-I, inhibitory neurons that are a focus of the report to which this Preview is directed.
GRPR, gastrin-releasing peptide receptor. Npra, natriuretic peptide receptor A is the receptor for the
B-type natriuretic peptide BNP, also known as Nppb. Image modified and reproduced under CC-BY
license: http://creativecommons.org/licenses/by/3.0/us/legalcode.
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Previewsrelationship between itch and pain. Dele-
tion of the neuronal-specific transcription
factor basic helix-loop-helix protein 5
(Bhlhb5) resulted in the loss of a subset
of inhibitory interneurons, termed B5-I
neurons, within the dorsal horn (Ross
et al., 2010). These mice scratched
without provocation and developed skin
lesions as a result. They were additionally
sensitive to pruritic agents, whereas
nociceptive responses to mechanical,
thermal, or chemical stimuli remained
unaffected.
A hallmark of itch is that it may be
alleviated by counterstimuli, consistent
with the existence of inhibitory control
pathways. The neural mechanisms and
neuromodulators underlying this phe-
nomenon have not been identified defini-
tively. The report from Kardon et al.
(2014) represents an important step in
addressing this knowledge gap. Dy-
norphin is a k-opioid neuropeptide
expressed in the CNS. Its precursor is
preprodynorphin. Dynorphin is stored in
large dense-core vesicles and is released
from nerve terminals, selectively acting on
k-opioid receptors (KORs) present in the504 Neuron 82, May 7, 2014 ª2014 Elsevier Iperipheral nervous system andCNS. Acti-
vation of KORs, which couple to Gi/G0,
leads to a decrease in synaptic transmis-
sion (Knoll and Carlezon, 2010). It was re-
ported previously that galanin-expressing
inhibitory interneurons coexpress dynor-
phin while also being a source of KORs
in the dorsal horn (Sardella et al., 2011).
Kardon et al. (2014) find that B5-I
neurons comprise a specific neurochem-
ical population of inhibitory interneurons
in the dorsal horn that inhibits itch. Using
immunostaining, they found that B5-I
neurons coexpress dynorphin and the
inhibitory neuropeptide galanin. These
mice also express another hallmark of
inhibitory neurons, the somatostatin re-
ceptor SST2A. Mice in which Bhlhb5 had
been knocked out showed almost a
complete loss of galanin- and dynor-
phin-expressing inhibitory interneurons,
a marked decrease in SST2A-expressing
neurons, but no change in SST2A-nega-
tive neurons.
The antipruritic effect of k-opioid
agonists was first identified in the early
1980s (reviewed by Cowan and Gmerek,
1986). These observations from almostnc.three decades ago continue to be sup-
ported by the current finding that scratch-
ing behavior, induced by a variety of
pruritogens, was inhibited after the
administration of k-opioid agonists, espe-
cially to Bhlhb5/ mice. Kardon et al.
(2014) hypothesized that the extensive
scratching in these knockout mice was
due to reduced k-opioid signaling asso-
ciated with the loss of dynorphin-pro-
ducing cells in the spinal cord. A critical
question then arises: is the elevated itch
in Bhlhb5/ mice due to the loss of
dynorphin, the lack of fast synaptic inhibi-
tion, or both? To address this question,
Kardon et al. (2014) examined mice in
which the dynorphin precursor had been
knocked out (PPD/). PPD/ mice
have not been reported to scratch spon-
taneously. It might be expected that
PPD/ mice would scratch more than
wild-type controls when itch is induced
by pruritogens, indicating an essential
role for dynorphin in pruritic inhibitory
circuits. However, PPD/ mice show
normal levels or scratching when
compared to wild-type animals. This
result suggests that the abnormal itch
phenotype observed in Bhlhb5/ ani-
mals is not completely dependent on
dynorphin. This finding suggests that
there is a degree of compensation for
the loss of dynorphin in PPD/ mice,
but not the loss of spinal neurons that
produce dynorphin. Together, these re-
sults suggest a role for dynorphin in
quelling acute and chronic itch but that
fast inhibitory neurotransmitters, such as
GABA and/or glycine, participate in the
relief of acute itch by scratching.
Neuropathic itch, a type of chronic itch
in people, is a particularly frustrating con-
dition. Shingles, caused by reactivation of
varicella in dorsal root ganglia, can cause
long-lasting and intense neuropathic pain.
It is less well-recognized that some vic-
tims suffer from an intense itch rather
than pain. The treatment of neuropathic
pain, and itch, is yielding somewhat to
neuromodulators. As Bhlhb5/ mice
scratch chronically, they may provide a
model of neuropathic itch. Kardon et al.
(2014) examined the capacity of k-opioid
agonists to relieve scratching in these
mice. Two structurally unrelated k-ago-
nists, nalfurafine and U-50,488, were
evaluated. Nalfurafine is approved in
Japan for the treatment of itch associated
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currently being evaluated in the U.S.
Nalfurafine and U-50,488 were delivered
by intraperitoneal injection and reduced
the time mice spent biting and/or licking
skin lesions. Histamine and nonhistamine
scratching, such as that evoked by chlo-
roquine, is mediated by distinct primary
afferents. Nalfurafine was known to
reduce scratching evoked by histamine,
a finding confirmed here. Nalfurafine and
U-50,488 also reduced scratching from
chloroquine. These results are consistent
with a merging of histamine and nonhist-
amine neural responses. To confirm that
the sensation of itch, and not nociceptive
pain, was being evaluated, Kardon et al.
(2014) employed the cheek model estab-
lished by Shimada and LaMotte (2008).
Capsaicin, which activates TrpV1 chan-
nels and is the active ingredient in hot
peppers, generates pain and itch re-
sponses that can be distinguished in this
model. Low doses of nalfurafine inhibited
only the scratching response, implying a
degree of selectivity with respect to the
treatment of itch versus pain.
Intrathecal injection of k-agonists or
antagonists was used by Kardon et al.
(2014) to delve into two additional ques-
tions. One question relates to the sequen-
tial path in which itch information is
relayed. Such information is relayed from
the periphery to the spinal cord by
upstream Nppb-expressing neurons that
communicate with downstream GRPR-
expressing neurons in the spinal cord.
The intrathecal injection of GRP is known
to evoke scratching. When Kardon et al.
(2014) coinjected GRP and nalfurafine,
scratching was reduced. This result
places the action of k-agonists and, by
inference, B5-I interneurons, downstream
of GRPR neurons. A second question is
whether blockade of KOR signaling would
increase an itch-associated response.
Intrathecal administration of k-antago-nists was used to answer this question
in the affirmative as such compounds
resulted in an increased behavioral
response to chloroquine. These findings
demonstrate the capacity of KOR
signaling in the spinal cord to modulate
itch up or down.
It is recognized that counterstimuli,
including noxious stimuli, scratching,
and cold, suppress itch. This suppression
occurs through the activation of inhibitory
pathways within the spinal cord (Bautista
et al., 2014). B5-I interneurons are well
positioned to be part of this milieu.
To examine this issue further, Kardon
et al. (2014) asked whether B5-I neurons
receive input from primary afferents
expressing TRPV1, TRPA1, and TRPM8,
channels that are activated by the
itch-inhibiting compounds capsaicin,
mustard oil, and menthol, respectively.
The answer, as tested using neurophysio-
logic techniques, was in the affirmative,
and a behavioral model was used as a
complementary approach. Specifically,
the topical application of menthol
decreased chloroquine-induced scratch-
ing behavior in wild-type mice but not in
Bhlhb5/ mice. These findings are
consistent with the concept that chemical
counterstimuli that ameliorate scratching
require B5-I neurons.
The findings in this paper provide a
lead for additional directions. k-opioid
agonists have been reported to be
helpful for certain itches. Why isn’t their
effect more general? What is the bal-
ance between KOR in the periphery
and the spinal cord with respect to
ameliorating itch? Might there be endog-
enous inhibitory mediators in addition to
dynorphin that are yet not identified?
And what is the role of fast synaptic
transmission in modulating itch, as sug-
gested by the observation that mice
lacking dynorphin still scratch? Address-
ing these questions will hopefully paveNeurothe way to new therapeutics for people
suffering from itch.ACKNOWLEDGMENTS
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